Aranesp Sales Down As Physicians Adopt Wait-And-See Posture – Amgen
Nineteen percent decline in U.S. sales of the erythropoiesis-stimulating agent versus Q2 2006 is a response to labeling change, regulatory climate, Amgen exec says.
Nineteen percent decline in U.S. sales of the erythropoiesis-stimulating agent versus Q2 2006 is a response to labeling change, regulatory climate, Amgen exec says.